Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to ...

Phase 1b US study planned for 2026, as company competes with NS Pharma and Avidity Biosciences in exon 44 space ...

The Netflix documentary “The Remarkable Life of Ibelin” tells Mats’ story, nearly 10 years after he passed away from a serious muscle condition. He touched countless lives through the online ...

Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...

WHO Wants To Be A Millionaire fans have been left baffled after a famous face used one of their lifelines on an ‘easy ...

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...

Shares of Entrada Therapeutics rose after regulators removed a clinical hold and said its lead product candidate could be studied as a treatment for Duchenne muscular dystrophy. The stock was up 9.5% ...

Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with ...

Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...

I'm fighting a fatal disease that took the life of my brother. I work in biotech and know there are medical advances that ...

Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for ...

At UMass Chan Medical School, researchers, doctors, patients and biomedical executives voiced their concerns over cuts to NIH ...